Trademark: 90606383
Word
TECSPIRET
Status
Dead
Status Code
605
Status Date
Friday, December 16, 2022
Serial Number
90606383
Mark Type
4000
Filing Date
Friday, March 26, 2021
Published for Opposition
Tuesday, December 14, 2021
Abandoned Date
Thursday, December 15, 2022

Trademark Owner History

Classifications
5 Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Trademark Events
Dec 16, 2022
Abandonment Notice E-Mailed - After Publication
Dec 16, 2022
Abandonment - After Publication
Dec 15, 2022
Teas Express Abandonment Received
Oct 28, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 28, 2022
Teas Change Of Correspondence Received
Oct 28, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 28, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 28, 2022
Teas Change Of Owner Address Received
Jul 20, 2022
Notice Of Approval Of Extension Request E-Mailed
Jul 18, 2022
Sou Extension 1 Granted
Jul 18, 2022
Sou Extension 1 Filed
Jul 18, 2022
Sou Teas Extension Received
Feb 8, 2022
Noa E-Mailed - Sou Required From Applicant
Dec 14, 2021
Official Gazette Publication Confirmation E-Mailed
Dec 14, 2021
Published For Opposition
Nov 24, 2021
Notification Of Notice Of Publication E-Mailed
Nov 5, 2021
Approved For Pub - Principal Register
Nov 3, 2021
Assigned To Examiner
Jul 2, 2021
New Application Office Supplied Data Entered
Mar 30, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24